This summary was created by AI, based on 2 opinions in the last 12 months.
The experts have mixed opinions on Teva Pharmaceutical, with one expert noting that the stock is cheap and has momentum, while another expert warns that the massive share price appreciation is not sustainable and the large debt load presents difficulties. Overall, it seems that the stock may have potential but also comes with significant risks that need to be considered.
Massive share price appreciation not sustainable.
Large debt load presents difficulties.
Does not own shares.
Would not recommend buying at this time.
Doesn't offer growth. The stock is weak and will stay weak.
Teva Pharmaceutical is a American stock, trading under the symbol TEVA-N on the New York Stock Exchange (TEVA). It is usually referred to as NYSE:TEVA or TEVA-N
In the last year, 2 stock analysts published opinions about TEVA-N. 0 analysts recommended to BUY the stock. 2 analysts recommended to SELL the stock. The latest stock analyst recommendation is . Read the latest stock experts' ratings for Teva Pharmaceutical.
Teva Pharmaceutical was recommended as a Top Pick by on . Read the latest stock experts ratings for Teva Pharmaceutical.
Earnings reports or recent company news can cause the stock price to drop. Read stock experts’ recommendations for help on deciding if you should buy, sell or hold the stock.
2 stock analysts on Stockchase covered Teva Pharmaceutical In the last year. It is a trending stock that is worth watching.
On 2024-03-27, Teva Pharmaceutical (TEVA-N) stock closed at a price of $14.43.
It's cheap and has momentum, but that's all it has now. It never grabbed him.